Albany, NY -- (SBWIRE) -- 11/21/2018 -- DelveInsight has announced the addition of the "Parkinson's disease (PD) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Parkinson's Disease for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report also covers the overview, treatment practices and Parkinson's disease forecasted epidemiology from 2018 to 2027, segmented by seven major markets.

Request for sample pages

Parkinson's Disease (PD) is a chronic and progressive movement disorder that primarily affects neurons in the substantia nigra area of the brain. It is due to loss of specific types of brain cells (neurons) that produce a chemical called Dopamine, which is usually responsible for the control and coordination process that is affected when the neuron malfunction and death occurs. Based on the onset of PD among the patients, the disease is classified as Juvenile Parkinson's Disease, Young-onset Parkinson's disease, and Idiopathic Parkinson's Disease. The female-to-male ratio for prevalent cases is different, most likely due to the survival differential between men and women with this disease. The high prevalence rate was found among males as compared to females in the United States.

Parkinson's disease is the 14th leading cause of death in the United States. The incidence of PD usually comprised of between 10 and 50 per 100,000 person-years and its prevalence is in between 100 and 300 per 100,000 population. The number of PD patients is expected to double by 2030 due to the general ageing of the population. PD is rare before the age of 50 years and its incidence and prevalence both increase progressively after age 60.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Acorda Therapeutics
2. Biogen
3. Orion Pharmaceuticals
4. Reviva
And many others

Drugs covered

1. Inbrija
2. Cinpanemab
3. ODM 104
4. RP5063
And many others

Report Scope
The report covers a descriptive overview of Parkinson's Disease, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Parkinson's Disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Parkinson's Disease are provided, along with an assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Parkinson's disease market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Parkinson's Disease market.